In May 2026, Stereotaxis reported first-quarter 2026 results and business updates, noting that its MAGiC robotic ablation catheter received U.S. FDA approval in January 2026 and is being utilized at sites in the U.S. and Europe. The company also said its Synchrony digital operating room system received FDA clearance in April 2026, with initial orders and shipments underway.
Revenue in the quarter reflected a transition: system revenue tied to Genesis installations and recurring revenue still influenced by the shift away from legacy catheter dependencies. For sales talent, that pattern—new platform ramp plus legacy wind-down—is common in robotic and capital-adjacent cardio.
Why Robotic Cardio Roles Feel Different
- Longer evaluations and proctoring cycles than consumable-only device bags
- Multi-stakeholder selling across electrophysiology, OR leadership, and administration
- Field teams need clinical adoption storytelling, not just case coverage logistics
- Hiring often blends capital discipline with high-touch case support in early sites
Career Signals for 2026
Candidates from consumable ortho or spine backgrounds should show how they learned capital workflows, training plans, and utilization metrics. Employers posting “robotics” roles should clarify whether the job is disposable pull-through, platform capital, or hybrid—and what ramp expectations are in year one.